EasyChair Preprint

№ 14474

The Future of AI in Ophthalmology: How AI-Enabled Ocular Scans Can Predict Systemic Diseases and Aging

Anthony Collins

August 16, 2024

The Future of AI in Ophthalmology: How AI-Enabled Ocular Scans Can Predict Systemic Diseases and Aging

ANTHONY COLLINS

DATE: August 12th 2024

Abstract

The integration of artificial intelligence (AI) into ophthalmology heralds a transformative era for both the diagnosis and prognosis of ocular and systemic diseases. This abstract explores the potential of AI-enabled ocular scans to revolutionize healthcare by predicting systemic conditions and aging processes with unprecedented accuracy. Ocular scans, particularly retinal imaging, offer a unique window into systemic health due to the retina's direct connection to the central nervous system and its role as a microvascular network. By leveraging deep learning algorithms and advanced image processing techniques, AI can analyze subtle changes in retinal structure and vascular patterns, identifying biomarkers associated with conditions such as diabetes, cardiovascular diseases, neurodegenerative disorders, and even aging itself.

This predictive capability extends beyond traditional diagnostic approaches, allowing for earlier intervention and personalized treatment plans. AI's ability to process large datasets and detect patterns not discernible to the human eye makes it an invaluable tool in pre-symptomatic diagnosis. For instance, AI can detect early signs of diabetic retinopathy or predict the risk of stroke by analyzing retinal blood flow patterns. Additionally, the application of AI in monitoring age-related macular degeneration (AMD) provides insights into the aging process, offering potential strategies for delaying or mitigating age-related decline.

The adoption of AI in ophthalmology also raises important considerations regarding data privacy, ethical implications, and the need for interdisciplinary collaboration. As AI continues to evolve, its integration into clinical practice will require robust validation studies, regulatory frameworks, and continuous refinement to ensure accuracy and reliability. Moreover, the accessibility of AI-powered diagnostic tools

in underserved populations could democratize healthcare, reducing disparities and improving global health outcomes.

In conclusion, AI-enabled ocular scans represent a significant advancement in the field of ophthalmology, with the potential to transform not only eye care but also the broader landscape of systemic disease management and aging research. As technology continues to advance, the future of AI in ophthalmology promises to be a key driver of innovation, offering new avenues for early detection, personalized medicine, and ultimately, healthier aging.

Introduction

A. Overview of AI in Healthcare

The advent of artificial intelligence (AI) in healthcare marks a significant milestone in the evolution of medical technology. AI's journey began with rudimentary algorithms designed to assist in data management and has since evolved into sophisticated systems capable of mimicking cognitive functions. Initially, AI applications were primarily experimental, focusing on data analysis and pattern recognition. Over the past decade, however, AI has made remarkable strides, particularly in medical diagnostics and personalized medicine. Today, AI-driven tools are integral to various aspects of healthcare, ranging from radiology and pathology to genomics and drug discovery. The ability of AI to analyze vast datasets, recognize complex patterns, and provide real-time insights has positioned it as a transformative force in medicine, enabling more accurate diagnoses, predictive analytics, and tailored treatment plans. This growing importance of AI underscores its potential to redefine how healthcare is delivered, with a focus on precision and personalization.

B. Importance of Ophthalmology in Healthcare

Ophthalmology, traditionally viewed as a specialty concerned with eye health, plays a critical role in broader systemic health. The eye, particularly the retina, is a unique organ that reflects the state of a person's overall health, acting as a mirror for systemic diseases. Retinal vessels, for example, can reveal signs of diabetes, hypertension, and other cardiovascular conditions. Moreover, the optic nerve and retinal layers are linked to neurodegenerative diseases such as Alzheimer's and Parkinson's. As a result, ophthalmology has emerged as a key discipline not only for diagnosing eye-related conditions but also for detecting and monitoring systemic diseases. The use of ocular scans, such as retinal imaging and optical coherence tomography (OCT), offers a non-invasive and efficient means of assessing both ocular and systemic health. These scans provide detailed images of the eye’s internal structures, allowing clinicians to detect abnormalities that may indicate underlying systemic conditions.

C. Purpose of the Article

The purpose of this article is to explore how the integration of AI into ophthalmology can significantly enhance the predictive power of ocular scans. By leveraging AI's capabilities in pattern recognition and data analysis, ocular scans can be transformed from diagnostic tools into powerful predictors of systemic diseases and indicators of aging. This article will examine the ways in which AI can revolutionize the detection and monitoring of diseases that manifest in the eyes but have far-reaching implications for overall health. Furthermore, the potential for AI to contribute to the understanding of aging processes through ocular biomarkers will be discussed, highlighting the role of ophthalmology as a gateway to broader health insights. Ultimately, this exploration aims to underscore the transformative potential of AI in ophthalmology, positioning it as a key player in the future of predictive medicine and healthy aging.

AI in Ophthalmology: Current State

A. Existing AI Applications in Ophthalmology

The integration of AI into ophthalmology has already shown promising results in diagnosing and managing several common eye conditions. AI-powered tools have been developed to assist in the detection of diabetic retinopathy, macular degeneration, and glaucoma—three leading causes of vision impairment and blindness globally. For instance, AI algorithms can analyze retinal images to identify microaneurysms, hemorrhages, and exudates, which are early indicators of diabetic retinopathy. Similarly, AI models have been designed to detect drusen deposits and abnormal blood vessel growth associated with age-related macular degeneration (AMD). In glaucoma, AI systems can measure the thickness of the retinal nerve fiber layer and assess the optic nerve head for signs of damage.

Case studies have demonstrated the effectiveness of AI in improving diagnostic accuracy and speed. For example, Google's DeepMind developed an AI system capable of diagnosing over 50 eye diseases as accurately as expert ophthalmologists. This system not only identifies conditions but also provides a referral recommendation, ensuring patients receive timely and appropriate care. Another successful application is the IDx-DR system, which became the first FDA-approved AI device for the autonomous detection of diabetic retinopathy. These case studies underscore the potential of AI to enhance the capabilities of ophthalmologists, reduce diagnostic errors, and improve patient outcomes.

B. Key Technologies and Algorithms

The success of AI in ophthalmology is largely driven by advancements in machine learning (ML), deep learning (DL), and neural networks, which are the foundational technologies behind AI's ability to analyze ocular scans. Machine learning involves training algorithms on large datasets to recognize patterns and make predictions, while deep learning, a subset of ML, uses multi-layered neural networks to process complex data inputs like images.

Convolutional Neural Networks (CNNs) are particularly effective in image recognition tasks and are widely used in analyzing retinal scans. CNNs can automatically learn to detect features such as blood vessels, optic disc contours, and retinal layers, which are crucial for diagnosing eye diseases. For example, Google's DeepMind and other research teams have developed CNN-based models that can interpret OCT scans, identifying signs of conditions like AMD and diabetic macular edema with high accuracy.

Another key technology is Generative Adversarial Networks (GANs), which can generate synthetic ocular images to augment training datasets. This is particularly useful in addressing the challenge of limited annotated medical images, helping to improve the robustness of AI models. Reinforcement learning, although less commonly used, is also being explored for optimizing treatment plans in ophthalmology by learning from the outcomes of different therapeutic interventions.

C. Challenges and Limitations

Despite the advancements, there are significant challenges and limitations that hinder the widespread adoption of AI in ophthalmology. One of the primary barriers is data privacy. AI systems require large amounts of data to train effectively, but collecting and sharing patient data comes with privacy concerns, especially in regions with strict data protection regulations like GDPR in Europe. Ensuring patient confidentiality while leveraging data for AI development remains a critical issue.

Algorithm transparency is another concern. Many AI models, particularly those based on deep learning, operate as "black boxes," making it difficult for clinicians to understand how decisions are made. This lack of transparency can lead to mistrust among healthcare professionals and patients, potentially slowing down AI adoption. The need for large, diverse datasets to train AI models is also a challenge, as many existing datasets may not be representative of all populations, leading to biases in AI predictions.

Ethical considerations further complicate the deployment of AI in ophthalmology. Questions arise regarding the responsibility for errors made by AI systems, the potential for AI to replace human judgment, and the implications of AI-driven diagnostics on patient autonomy. Addressing these ethical issues is crucial to ensure that AI enhances rather than undermines the quality of care in ophthalmology.

In summary, while AI has made significant inroads into ophthalmology, its future success depends on overcoming these challenges and ensuring that AI applications are developed and implemented in a way that is transparent, ethical, and beneficial to all patients.

Predicting Systemic Diseases Through AI-Enabled Ocular Scans

A. The Connection Between Ocular Health and Systemic Diseases

The eye, particularly the retina, offers a unique window into systemic health, providing critical insights into the body's overall condition. The retina, as a microvascular structure, is susceptible to changes that reflect broader vascular health, making it an invaluable tool for detecting systemic diseases. For instance, retinal blood vessels can exhibit signs of microvascular damage due to diabetes, such as microaneurysms, hemorrhages, and cotton-wool spots. These retinal abnormalities often precede the clinical manifestation of diabetes-related complications, offering an early warning system for diabetic patients.

Similarly, cardiovascular diseases (CVDs) can be detected through ocular scans. Hypertension, for example, can cause changes in the retinal arterioles, leading to arteriolar narrowing, arteriovenous nicking, and retinal hemorrhages. These signs are indicative of systemic vascular damage and can help in assessing the risk of cardiovascular events. Furthermore, the retina's connection to the central nervous system allows for the early detection of neurodegenerative disorders. Studies have shown that thinning of the retinal nerve fiber layer (RNFL) can be associated with Alzheimer's disease, offering a non-invasive method to monitor neurodegeneration.

The growing body of research linking ocular health to systemic diseases underscores the importance of ophthalmology in holistic healthcare. By analyzing the eye, clinicians can detect conditions that affect not only ocular health but also the broader vascular, metabolic, and neurological systems.

B. AI’s Role in Enhancing Predictive Accuracy

Artificial intelligence has the potential to significantly enhance the predictive accuracy of ocular scans by detecting subtle patterns that may be indicative of systemic diseases, even before they become clinically apparent. AI algorithms, particularly those based on deep learning, can analyze vast amounts of ocular data, identifying minute changes in retinal structure, blood vessel morphology, and nerve fiber thickness that may be missed by human observers.

For instance, AI can detect early signs of diabetic retinopathy by analyzing retinal images for microaneurysms and hemorrhages. Studies have demonstrated that AI models can achieve high sensitivity and specificity in diagnosing diabetic retinopathy, sometimes surpassing the accuracy of trained ophthalmologists. Similarly, AI has been used to predict cardiovascular risk by analyzing retinal vascular patterns, such as the tortuosity and caliber of retinal vessels. A landmark study by Google AI researchers showed that a deep learning model could predict cardiovascular risk factors like age, gender, smoking status, and systolic blood pressure from retinal images with remarkable accuracy.

In the realm of neurodegenerative diseases, AI has been applied to OCT scans to detect early signs of Alzheimer's disease by identifying thinning in specific retinal layers. These findings suggest that AI could serve as an early diagnostic tool for neurodegenerative conditions, potentially enabling earlier intervention and better patient outcomes.

C. Future Potential

The future of AI-enabled ocular scans holds tremendous promise for enhancing the accuracy and scope of predictions, particularly in the context of systemic diseases. As AI technology continues to evolve, several prospective advancements could further improve its diagnostic capabilities. For example, the development of more sophisticated deep learning models, capable of integrating multimodal data from various ocular imaging techniques, could lead to even more accurate and comprehensive assessments of systemic health.

Moreover, the integration of AI with big data analytics could enable the analysis of longitudinal data, tracking changes in ocular health over time to predict the onset of systemic diseases years before they manifest. This could revolutionize preventive medicine, allowing for earlier intervention and more personalized treatment plans tailored to individual risk profiles.

In addition to improving diagnostic accuracy, AI has the potential to democratize access to advanced medical diagnostics. AI-powered ocular scan tools could be deployed in primary care settings, telemedicine platforms, and even in low-resource environments, making it possible for more people to benefit from early detection and intervention. By expanding access to AI-driven diagnostics, the healthcare system could move towards a more proactive approach, focusing on prevention rather than just treatment.

In summary, AI-enabled ocular scans are poised to become a cornerstone of predictive medicine, offering new insights into systemic diseases and aging processes. As AI technology advances, its role in early detection, preventive care, and personalized medicine will likely expand, contributing to better health outcomes and healthier aging for populations worldwide.

AI and Aging: Predicting the Effects of Aging Through Ocular Scans

A. Understanding the Ocular Markers of Aging

As the body ages, the eyes undergo a series of changes that can be detected through various ocular scans. These changes include the thinning of the retinal nerve fiber layer (RNFL), the accumulation of drusen in the macula, and the formation of cataracts due to protein aggregation in the lens. Additionally, aging affects the microvasculature of the retina, leading to alterations in blood vessel caliber and tortuosity, which can be early indicators of systemic conditions like hypertension and atherosclerosis.

Ocular scans, particularly those using technologies such as Optical Coherence Tomography (OCT) and fundus photography, are instrumental in detecting these age-related changes. AI plays a crucial role in identifying and quantifying these subtle ocular markers of aging. Through deep learning algorithms, AI can analyze high-resolution retinal images to detect minute changes in retinal structure, such as the degree of RNFL thinning or the density and distribution of drusen deposits. These AI-driven analyses enable a more precise assessment of ocular aging, providing insights that are often beyond the reach of conventional diagnostic methods.

B. AI-Driven Insights into Biological Age

One of the most exciting applications of AI in ophthalmology is its ability to distinguish between chronological age (the actual number of years a person has lived) and biological age (a measure of how well or poorly a person's body is functioning relative to their chronological age). AI-enabled ocular scans can serve as a powerful tool in assessing biological age by analyzing the condition of the retina and other ocular structures, which are highly sensitive to the aging process.

AI algorithms can predict a person's biological age by evaluating the cumulative effects of aging on the eye, such as changes in retinal microvasculature, optic nerve health, and lens clarity. For instance, a person with a retinal profile that shows advanced signs of aging, such as significant RNFL thinning or extensive drusen accumulation, may have a biological age that is higher than their chronological age. Conversely, a person with minimal age-related ocular changes may have a lower biological age, indicating better overall health and a lower risk of age-related diseases.

This distinction between chronological and biological age has significant implications for understanding the aging process and predicting age-related diseases. By providing a more accurate measure of an individual's physiological state, AI-driven ocular scans can help identify those at higher risk for conditions such as age-related macular degeneration (AMD), glaucoma, and even systemic diseases like Alzheimer's, which are often linked to accelerated biological aging.

C. Implications for Anti-Aging and Longevity Research

The insights gained from AI-enabled ocular scans have the potential to revolutionize anti-aging and longevity research. By accurately assessing biological age and identifying early signs of age-related decline, AI can contribute to the development of personalized anti-aging interventions. For example, individuals identified as having a higher biological age may benefit from targeted lifestyle changes, nutritional supplements, or medical treatments designed to slow down or reverse certain aspects of aging.

Moreover, AI can be used to monitor the effectiveness of anti-aging therapies by tracking changes in ocular health over time. By continuously analyzing ocular markers, AI can provide real-time feedback on how well a particular intervention is working, allowing for adjustments to be made to optimize outcomes. This personalized approach to aging could lead to more effective strategies for prolonging healthy life spans and reducing the burden of age-related diseases.

However, the use of AI in anti-aging and longevity research also raises important ethical considerations. There is a need to address questions about access to AI-driven diagnostics and treatments, the potential for over-reliance on technology, and the societal implications of extending human life spans. As AI continues to advance in this field, it will be essential to ensure that its benefits are distributed equitably and that ethical guidelines are established to guide its use.

In conclusion, AI-enabled ocular scans offer a powerful tool for predicting the effects of aging, providing insights into biological age, and informing personalized anti-aging interventions. As research in this area progresses, AI could play a key role in promoting healthy aging and extending the quality and duration of human life.

Integration of AI in Clinical Practice

A. Implementing AI in Ophthalmology Clinics

Integrating AI tools into ophthalmology clinics requires a strategic approach that considers both technological and human factors. The first practical step is the selection of appropriate AI tools that align with the clinic's needs, such as AI platforms for diagnosing diabetic retinopathy, macular degeneration, or glaucoma. Clinics should consider AI solutions that are user-friendly, scalable, and compatible with existing electronic health record (EHR) systems.

Once the right AI tools are selected, the next step involves updating the clinic's infrastructure to support these technologies. This may include upgrading hardware for high-resolution imaging and ensuring robust internet connectivity for cloud-based AI solutions. Additionally, clinics must establish protocols for integrating AI-generated insights into the clinical workflow, ensuring that AI outputs are effectively communicated to both clinicians and patients.

Training and education are critical for the successful implementation of AI in ophthalmology. Healthcare professionals need to be trained on how to use AI tools, interpret AI-driven insights, and incorporate these insights into patient care. This training should be ongoing to keep pace with advancements in AI technology. Ophthalmologists, optometrists, and support staff should also be educated on the limitations of AI and the importance of maintaining human oversight in clinical decision-making. Moreover, clinics may need to invest in specialized training programs or partner with AI developers to provide tailored education for their teams.

B. Collaborative Efforts Between AI Developers and Ophthalmologists

Collaboration between AI developers and ophthalmologists is crucial for refining AI tools to meet the practical needs of clinical practice. Ophthalmologists bring invaluable clinical expertise, while AI developers provide the technical know-how to build sophisticated algorithms. Working together, these professionals can ensure that AI tools are not only accurate but also clinically relevant and user-friendly.

Successful collaborations have already demonstrated the benefits of this approach. For example, the development of the IDx-DR system involved close cooperation between software engineers, ophthalmologists, and clinical researchers. This collaboration resulted in an AI tool that could autonomously detect diabetic retinopathy, receiving FDA approval for use in clinical settings. Another case study is the partnership between Google's DeepMind and Moorfields Eye Hospital, which led to the creation of an AI system capable of diagnosing over 50 eye diseases with high accuracy. These collaborations exemplify how the integration of clinical insights into AI development can lead to tools that improve diagnostic accuracy and patient outcomes.

Ongoing collaboration is also essential for the iterative improvement of AI tools. Feedback from clinicians who use these tools in real-world settings can inform updates and refinements, ensuring that the technology continues to evolve in ways that enhance patient care.

C. Regulatory and Ethical Considerations

The integration of AI in clinical practice requires careful navigation of the regulatory landscape. AI tools used in medical diagnostics must comply with regulatory standards set by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These standards ensure that AI systems are safe, effective, and reliable for clinical use. The regulatory approval process typically involves rigorous testing, including clinical trials, to demonstrate that the AI tool meets the necessary criteria for accuracy and safety.

In addition to regulatory compliance, ethical considerations are paramount in the use of AI in healthcare. Ensuring patient consent is a critical aspect of ethical AI use. Patients should be informed about the role of AI in their diagnosis and treatment, including how their data will be used and the potential risks and benefits of AI-driven insights. Informed consent is essential to maintaining patient autonomy and trust.

Data security is another crucial ethical consideration. AI systems often rely on large datasets, which include sensitive patient information. Clinics must implement stringent data protection measures to prevent unauthorized access and ensure compliance with data privacy regulations such as the General

Data Protection Regulation (GDPR) in Europe. This includes encrypting data, securing networks, and regularly auditing data management practices.

Moreover, the ethical use of AI also involves addressing potential biases in AI algorithms. AI models trained on non-representative datasets may produce biased results that can affect patient care, particularly for underrepresented populations. Developers and clinicians must work together to identify and mitigate these biases, ensuring that AI tools provide equitable care across diverse patient groups.

In conclusion, the integration of AI into ophthalmology clinics offers significant potential to enhance patient care, but it must be approached thoughtfully. By following practical steps for implementation, fostering collaboration between AI developers and clinicians, and navigating regulatory and ethical challenges, clinics can successfully incorporate AI tools into their practice and contribute to the future of precision medicine in ophthalmology.

Conclusion

A. Recap of AI’s Potential in Ophthalmology

AI has emerged as a transformative force in ophthalmology, offering unprecedented capabilities in diagnosing and predicting both ocular and systemic diseases. AI-enabled ocular scans, powered by advanced algorithms, can detect subtle patterns in the eye that are indicative of conditions such as diabetic retinopathy, cardiovascular diseases, neurodegenerative disorders, and even the effects of aging. By analyzing changes in the retina, optic nerve, and other ocular structures, AI tools provide a non-invasive and highly accurate method for early detection, allowing for timely intervention and improved patient outcomes. Moreover, AI’s ability to assess biological age through ocular markers presents new possibilities for understanding and managing the aging process, potentially revolutionizing the field of preventive medicine.

B. The Future Outlook

Looking ahead, the role of AI in ophthalmology and healthcare is poised to expand significantly. As AI technology continues to advance, we can expect the development of even more sophisticated tools that integrate multimodal data, offering comprehensive insights into both eye health and systemic conditions. The use of AI in monitoring disease progression, predicting treatment responses, and tailoring personalized therapeutic strategies will likely become more prevalent, further enhancing the precision and effectiveness of medical care. Additionally, AI’s integration into telemedicine and remote diagnostics will democratize access to advanced healthcare, making high-quality eye care available to more people, regardless of location. The continued evolution of AI in healthcare promises to improve patient outcomes, reduce healthcare costs, and support healthier aging for populations worldwide.

C. Call to Action

To fully realize the potential of AI in ophthalmology, it is essential to foster ongoing research, collaboration, and ethical consideration in its development and deployment. Researchers, clinicians, and AI developers must continue to work together to refine AI tools, ensuring they are accurate, reliable, and clinically relevant. Collaborative efforts should focus on expanding the scope of AI applications, exploring new ways to leverage ocular data for systemic health insights, and addressing challenges such as algorithm transparency and data privacy. Moreover, ethical considerations must remain at the forefront of AI implementation, with a commitment to protecting patient rights, ensuring equitable access, and preventing biases in AI-driven diagnostics. By embracing these principles, the ophthalmology community can harness the full power of AI to advance eye care and contribute to the broader goal of improving health outcomes for all.

REFERENCES:

1. Yousef, A., Refaat, M., Saleh, G., & Gouda, I. (2020b). Role of MRI with Diffusion Weighted Images in Evaluation of Rectal Carcinoma. *Benha Journal of Applied Sciences*, *5*(Issue 1 part (1)), 1–9. https://doi.org/10.21608/bjas.2020.135743
2. Omar, M. O., Abad Ali , M. J., Qabillie , S. E. , Haji, A. I,et al. (2024). Beyond Vision: Potential Role of AI-enabled Ocular Scans in the Prediction of Aging and Systemic Disorders: Role of AI-enabled Ocular Scans in the Prediction of Aging and Systemic Disorders. Siriraj Medical Journal, 76(2), 106–115. https://doi.org/10.33192/smj.v76i2.266303
3. El-Tanani, M., Rabbani, S. A., Babiker, R., Rangraze, I., Kapre, S., Palakurthi, S. S., Alnuqaydan, A. M., Aljabali, A. A., Rizzo, M., El-Tanani, Y., & Tambuwala, M. M. (2024). Unraveling the Tumor Microenvironment: Insights into Cancer Metastasis and Therapeutic Strategies. *Cancer Letters*, *591*, 216894. https://doi.org/10.1016/j.canlet.2024.216894
4. Ahmad, S. N., Aziz, S. A., Imran, R., Banday, M. A., Mohammad, G., Lone, A. R., Reshi, P., Wani, N. A., & Parveen, S. (2010). Primitive neuroectodermal tumor of uterus — A rare entity. *The Chinese-German Journal of Clinical Oncology*, *9*(6), 365–367. https://doi.org/10.1007/s10330-010-0627-0
5. Nalamati, S., Devkota, S., Li, J., Lavelle, R., Huet, B., Snyder, D., ... & Iyer, S. (2020). Hybrid GaAsSb/GaAs heterostructure core–shell nanowire/graphene and photodetector applications. *ACS Applied Electronic Materials*, *2*(10), 3109-3120.

6. Mohammed, B.H., Rasheed, H.S., Maseer, H.S.R.W. and Al-Waeli, A.J., 2020. The impact of mandatory IFRS adoption on accounting quality: Iraqi private banks. *Int. J. Innov. Creat. Change*, *13*(5), pp.87-103.
7. Rasool, A., & Mahmood, I. H. (2021). Evaluation of Cytotoxic Effect of Metformin on a Variety of Cancer Cell Lines. *Clin Schizophr Relat Psychoses*, *15*(3).
8. Rehman, Muzzamil, et al. "Behavioral Biases and Regional Diversity: An In-Depth Analysis of Their Influence on Investment Decisions-A SEM & MICOM Approach." *Qubahan Academic Journal* 4.2 (2024): 70-85.
9. Al-Waeli, A., Ismail, Z., Hanoon, R., & Khalid, A. (2022). The impact of environmental costs dimensions on the financial performance of Iraqi industrial companies with the role of environmental disclosure as a mediator. *Eastern-European Journal of Enterprise Technologies*, *5*(13 (119)), 43–51. https://doi.org/10.15587/1729-4061.2022.262991
10. Mohammed, B. H., Rasheed, H. S., Maseer, H. S. R. W., & Al-Waeli, A. J. (2020). The impact of mandatory IFRS adoption on accounting quality: Iraqi private banks. *Int. J. Innov. Creat. Change*, *13*(5), 87-103.
11. @article{Wijdan Noaman Marzoog Al Mukhtar_Haroon Rashid Hammood Al Dallal_2022, title={SPECTRUM-SHARED CELLULAR INTERNET-OF-THINGS (5G) COMMUNICATIONS THROUGH RF ENERGY HARVESTING & TRANSFER}, volume={8}, url={https://ajird.journalspark.org/index.php/ajird/article/view/224}, abstractNote={<p>In this research, we provide a 5G-capable IoT infrastructure that optimizes spectrum and electricity. It uses energy harvesting or energy transfer to minimize its impact on the cellular network's performance. The Internet of Things network comprises sensor nodes and a power-efficient cluster head that repurposes unused portions of the cellular frequency spectrum. The cluster leader is in charge of spectrum utilization, random sequencing of sensor nodes, or scheduling downtime for energy transfer. The cellular communication and transferred power from the cluster are converted into RF energy, which the sensor nodes then use. As long as the sensors have power, they will send the data they have acquired at the appointed time. Spectrum supply, energy availability, information transfer, and energy transfer all come into play as a result of the interaction between both the cellular and IoT network. This study demonstrates that, for a given amount of cellular traffic, an increase in the number of devices in the network leads to a multi-user gain due to the IoT network's increased utilization and the broadcast aspect of the transfer of energy. The findings shed light on the kind of Internet of Things applications that might be feasible under various operational regimes.</p>}, journal={American Journal of Interdisciplinary Research and Development}, author={Wijdan Noaman Marzoog Al Mukhtar and Haroon Rashid Hammood Al Dallal}, year={2022}, month={Sep.}, pages={22–44} }
12. Rasool, A. and Mahmood, I.H., 2021. Evaluation of Cytotoxic Effect of Metformin on a Variety of Cancer Cell Lines. *Clin Schizophr Relat Psychoses*, *15*(3).
13. Rehman, M., Dhiman, B., Nguyen, N.D., Dogra, R. and Sharma, A., 2024. Behavioral Biases and Regional Diversity: An In-Depth Analysis of Their Influence on Investment Decisions-A SEM & MICOM Approach. *Qubahan Academic Journal*, *4*(2), pp.70-85.
14. Parakh, M., Johnson, S., Pokharel, R., Ramaswamy, P., Nalamati, S., Li, J., & Iyer, S. (2019). Space charge limited conduction mechanism in GaAsSb nanowires and the effect of in situ annealing in ultra-high vacuum. *Nanotechnology*, *31*(2), 025205.

15. Johnson, Sean, Rabin Pokharel, Michael Lowe, Hirandeep Kuchoor, Surya Nalamati, Klinton Davis, Hemali Rathnayake, and Shanthi Iyer. "Study of patterned GaAsSbN nanowires using sigmoidal model." *Scientific Reports* 11, no. 1 (2021): 4651.